Literature DB >> 2444121

Human visceral leishmaniasis: analysis of the specificity of humoral immune response to polypeptides of Leishmania donovani chagasi.

J I dos Santos1, M G Morgado, B Galvão-Castro.   

Abstract

Soluble antigens from Leishmania donovani chagasi were studied in terms of their ability to react with sera from human visceral leishmaniasis. Thirty-six polypeptides, with molecular weights ranging from 14,400 to 123,000 were demonstrated by Western blot analysis. An extensive cross-reactivity with sera from patients with cutaneous leishmaniasis and Chagas' disease also was observed. Two polypeptides (Mr 119,000 and 123,000) reacted with all the sera from visceral leishmaniasis patients. When they were electroeluted from gels and evaluated with respect to specificity to the L. donovani chagasi subspecies, these components were expressed in all strains of Leishmania tested, but not in those of Trypanosoma cruzi. These results indicated that these components are shared by Trypanosomatidae of genus Leishmania. The eluted polypeptides did not react with sera from patients with Chagas' disease, indicating the feasibility of using purified antigens to discriminate between the humoral immune responses in T. cruzi and Leishmania infections.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2444121     DOI: 10.4269/ajtmh.1987.37.263

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  13 in total

1.  Identification of a Western blot pattern for the specific diagnosis of Trypanosoma cruzi infection in human sera.

Authors:  Cristina Riera; Mireia Verges; Laura Iniesta; Roser Fisa; Montserrat Gállego; Silvia Tebar; Montserrat Portús
Journal:  Am J Trop Med Hyg       Date:  2012-03       Impact factor: 2.345

2.  Induction of complement-sensitivity in Leishmania amazonensis metacyclic promastigotes by protease treatment but not by specific antibodies.

Authors:  N M Soares; E M Carvalho; R T Pinho; L C Pontes de Carvalho
Journal:  Parasitol Res       Date:  1993       Impact factor: 2.289

3.  Immunoglobulin G subclass-specific antileishmanial antibody responses in Indian kala-azar and post-kala-azar dermal leishmaniasis.

Authors:  A K Ghosh; S Dasgupta; A C Ghose
Journal:  Clin Diagn Lab Immunol       Date:  1995-05

4.  Immunoblot analysis of Leishmania panamensis antigens in sera of patients with American cutaneous leishmaniasis.

Authors:  D M Isaza; M Restrepo; W Mosca
Journal:  J Clin Microbiol       Date:  1997-12       Impact factor: 5.948

5.  Serodiagnosis of anthroponotic cutaneous leishmaniasis (ACL) caused by Leishmania tropica in Sanliurfa Province, Turkey, where ACL Is highly endemic.

Authors:  Fadile Yildiz Zeyrek; Metin Korkmaz; Yusuf Ozbel
Journal:  Clin Vaccine Immunol       Date:  2007-08-29

6.  Immunoblot analysis of the humoral immune response to Leishmania donovani polypeptides in cases of human visceral leishmaniasis: its usefulness in prognosis.

Authors:  Promod Kumar; Kalpana Pai; Kiran Tripathi; H P Pandey; Shyam Sundar
Journal:  Clin Diagn Lab Immunol       Date:  2002-09

7.  Immunoblot analysis of the humoral immune response to Leishmania donovani infantum polypeptides in human visceral leishmaniasis.

Authors:  L Rolland-Burger; X Rolland; C W Grieve; L Monjour
Journal:  J Clin Microbiol       Date:  1991-07       Impact factor: 5.948

8.  Recombinant Leishmania Hsp90 and Hsp70 are recognized by sera from visceral leishmaniasis patients but not Chagas' disease patients.

Authors:  C R de Andrade; L V Kirchhoff; J E Donelson; K Otsu
Journal:  J Clin Microbiol       Date:  1992-02       Impact factor: 5.948

9.  Characterization of immunoglobulin G and its subclass response to Indian kala-azar infection before and after chemotherapy.

Authors:  Rajesh Ravindran; Khairul Anam; Bibhas C Bairagi; Bibhuti Saha; Netai Pramanik; Subhasis K Guha; Rama P Goswami; Dwijadas Banerjee; Nahid Ali
Journal:  Infect Immun       Date:  2004-02       Impact factor: 3.441

10.  Heterogeneous antibody responses in tuberculosis.

Authors:  K Lyashchenko; R Colangeli; M Houde; H Al Jahdali; D Menzies; M L Gennaro
Journal:  Infect Immun       Date:  1998-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.